Free Trial
NASDAQ:CHGA

Avalon GloboCare Q4 2025 Earnings Results & Report

Avalon GloboCare logo
$2.02 +0.01 (+0.50%)
As of 10/9/2026 04:00 PM Eastern

Avalon GloboCare reported Q4 2025 earnings on March 30, 2026. The company reported EPS of $9.20.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Avalon GloboCare EPS Results

Actual EPS
$9.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Avalon GloboCare Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Avalon GloboCare Q4 2025 Earnings FAQ

Avalon GloboCare (NASDAQ:CHGA) reported earnings of $9.20 per share for Q4 2025. The report was announced on Monday, March 30, 2026.

Avalon GloboCare Earnings Headlines

Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
See More Avalon GloboCare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avalon GloboCare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalon GloboCare and other key companies, straight to your email.

About Avalon GloboCare

Avalon GloboCare (NASDAQ:CHGA) is a biotechnology company focused on developing cell-based and regenerative medicine technologies. Its work has included cellular immunotherapies, exosome-based products and other platforms intended to support the treatment of cancer and other serious medical conditions.

The company has also pursued activities involving cell and gene therapy development, biobanking and related laboratory services. Avalon GloboCare has described its business as spanning research, product development and potential commercialization through collaborations and strategic partnerships.

Avalon GloboCare was founded in the United States and has historically been associated with operations in New Jersey. Publicly available company materials have identified David Jin as a senior executive, although the company’s operating status, leadership and securities information may have changed. Avalon GloboCare has historically traded under the symbol AVCO; the symbol provided, CHGA, could not be independently confirmed as its current listing.

View Avalon GloboCare Profile